1-4 of 4
Ross Henderson
Close
Sort by
Journal Articles

Once Weekly Subcutanous Bortezomib with Cyclophosphamide and Dexamethasone Is Well Tolerated and Effective As Initial Treatment in Symptomatic Multiple Myeloma

David Simpson, FRACP, FRCPA, MBChB, James Liang, MBChB, Ross Henderson, MBChB, PhD, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Eileen Merriman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2012) 120 (21): 4049.
https://doi.org/10.1182/blood.V120.21.4049.4049
Published: 2012
Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD
Journal: Blood
Blood (2010) 116 (21): 1961.
https://doi.org/10.1182/blood.V116.21.1961.1961
Published: 2010
Journal Articles

Thalidomide: An Active Agent in AILT Lymphoma

Ross Henderson, David Simpson, MBChB, FRACP, FRCPA, Merit Hanna, MBChB, FRCPA, Sanjeev Chunilal
Journal: Blood
Blood (2008) 112 (11): 4960.
https://doi.org/10.1182/blood.V112.11.4960.4960
Published: 2008
Journal Articles

Antibodies Targeting Subunit 1 of the N -Methyl-D-Aspartate Receptor May Contribute to Immune Mediated Thrombocytopenia.

Maggie L. Kalev-Zylinska, MD, PhD, FRCPA, Hilary A. Blacklock, Gordon Royle, Ross Henderson, Peter Flanagan, Sharon Jackson, Isuru Dilshan, Wymond Symes, Kathryn Goldstone, Peter Browett, Matthew J. During
Journal: Blood
Blood (2007) 110 (11): 2110.
https://doi.org/10.1182/blood.V110.11.2110.2110
Published: 2007